4 DNA Dependent DNA Polymerases as Targets for Low-Weight …
129
29. Sutton MD, Walker GC (2001) Managing DNA polymerases: coordinating DNA replication,
DNA repair, and DNA recombination. Proc Natl Acad Sci U S A 98(15):8342–8349
30. Ohmori H, Hanafusa T, Ohashi E, Vaziri C (2009) Separate roles of structured and unstructured regions of Y-family DNA polymerases. Adv Protein Chem Struct Biol 78:99–146
31. Öberg B (2006) Rational design of polymerase inhibitors as antiviral drugs. Antiviral Res.
71(2–3):90–95
32. Wright GE, Brown NC (1990) Deoxyribonucleotide analogs as inhibitors and substrates of
DNA polymerases. Pharmacol Ther 47(3):447–497
33. Razonable RR (2011) Antiviral drugs for viruses other than human immunodeficiency virus.
Mayo Clin Proc 86(10):1009–1026
34. De Clercq E (2007) The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res 75:1–13
35. Magee WC, Evans DH (2012) The antiviral activity and mechanism of action of (S)-[3-hydroxy-2-(phosphonomethoxy)propyl] (HPMP) nucleosides. Antiviral Res 96(2):169–180
36. Merta A, Votruba I, Rosenberg I, Otmar M, Hrebabecký H, Bernaerts R, Holý A (1990) Inhibition of herpes simplex virus DNA polymerase by diphosphates of acyclic phosphonylmethoxyalkyl nucleotide analogues. Antiviral Res 13(5):209–218
37. Xiong X, Smith JL, Kim C, Huang ES, Chen MS (1996) Kinetic analysis of theinteraction of
cidofovir diphosphate with human cytomegalovirus DNApolymerase. Biochem Pharmacol
51:1563–1567
38. Xiong X, Smith JL, Chen MS (1997) Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob Agents Chemother
41:594–599
39. Magee WC, Hostetler KY, Evans DH (2005) Mechanism of inhibition of vaccinia virus DNA
polymerase by cidofovir diphosphate. Antimicrob Agents Chemother 49, 3153–3162
40. Magee WC, Aldern KA, Hostetler KY, Evans DH (2008) Cidofovir and (S)-9-[3-hydroxy-(2phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA
polymerase when incorporated into the template strand. Antimicrob Agents Chemother 52,
586–597
41. Birkus G, Rejman D, Otmar M, Votruba I, Rosenberg I, Holy A (2004) The substrate activity
of (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine diphosphate toward DNA polymerases alpha, delta and epsilon. Antivir Chem Chemother 15:23–33
42. Magee WC, Valiaeva N, Beadle JR, Richman DD, Hostetler KY, Evans DH (2011) Antimicrob Agents Chemother 55(11):5063–5072
43. De Clercq E (2011) The clinical potential of the acyclic (and cyclic) nucleoside phosphonates.
The magic of the phosphonate bond. Biochem Pharmacol 82:99–109
44. Andrei G, Snoeck R (2010) Cidofovir activity against poxvirus infections. Viruses 2(12):
2803–2830
45. Corey L, Benedetti J, Critchlow C, Mertz G, Douglas J, Fife K, Fahnlander A, Remington
ML, Winter C, Dragavon J (1983) Treatment of primary first-episode genital herpes simplex
virus infections with acyclovir: results of topical, intravenous and oral therapy. J Antimicrob
Chemother 12(Suppl B):79–88
46. Serota FT, Starr SE, Bryan CK, Koch PA, Plotkin SA, August CS (1982) Acyclovir treatment
of herpes zoster infections: use in children undergoing bone marrow transplantation. JAMA
247:2132–2135
47. De Clercq E (2004) Discovery and development of BVDU (brivudin) as a therapeutic for the
treatment of herpes zoster. Biochem Pharmacol 68:2301–2315
48. Superti F, Ammendolia MG, Marchetti M (2008) New advances in anti-HSV chemotherapy.
Curr Med Chem 15:900–911
49. Nichols WG, Boeckh M (2000) Recent advances in the therapy and prevention of CMV infections. J Clin Virol 16:25–40
50. Sarisky RT, Bacon TH, Boon RJ, Duffy KE, Esser KM, Leary J, Locke LA, Nguyen TT, Quail
MR, Saltzman R (2003) Profiling penciclovir susceptibility and prevalence of resistance of
herpes simplex virus isolates across eleven clinical trials. Arch Virol 148(9):1757–1769
129
29. Sutton MD, Walker GC (2001) Managing DNA polymerases: coordinating DNA replication,
DNA repair, and DNA recombination. Proc Natl Acad Sci U S A 98(15):8342–8349
30. Ohmori H, Hanafusa T, Ohashi E, Vaziri C (2009) Separate roles of structured and unstructured regions of Y-family DNA polymerases. Adv Protein Chem Struct Biol 78:99–146
31. Öberg B (2006) Rational design of polymerase inhibitors as antiviral drugs. Antiviral Res.
71(2–3):90–95
32. Wright GE, Brown NC (1990) Deoxyribonucleotide analogs as inhibitors and substrates of
DNA polymerases. Pharmacol Ther 47(3):447–497
33. Razonable RR (2011) Antiviral drugs for viruses other than human immunodeficiency virus.
Mayo Clin Proc 86(10):1009–1026
34. De Clercq E (2007) The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res 75:1–13
35. Magee WC, Evans DH (2012) The antiviral activity and mechanism of action of (S)-[3-hydroxy-2-(phosphonomethoxy)propyl] (HPMP) nucleosides. Antiviral Res 96(2):169–180
36. Merta A, Votruba I, Rosenberg I, Otmar M, Hrebabecký H, Bernaerts R, Holý A (1990) Inhibition of herpes simplex virus DNA polymerase by diphosphates of acyclic phosphonylmethoxyalkyl nucleotide analogues. Antiviral Res 13(5):209–218
37. Xiong X, Smith JL, Kim C, Huang ES, Chen MS (1996) Kinetic analysis of theinteraction of
cidofovir diphosphate with human cytomegalovirus DNApolymerase. Biochem Pharmacol
51:1563–1567
38. Xiong X, Smith JL, Chen MS (1997) Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob Agents Chemother
41:594–599
39. Magee WC, Hostetler KY, Evans DH (2005) Mechanism of inhibition of vaccinia virus DNA
polymerase by cidofovir diphosphate. Antimicrob Agents Chemother 49, 3153–3162
40. Magee WC, Aldern KA, Hostetler KY, Evans DH (2008) Cidofovir and (S)-9-[3-hydroxy-(2phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA
polymerase when incorporated into the template strand. Antimicrob Agents Chemother 52,
586–597
41. Birkus G, Rejman D, Otmar M, Votruba I, Rosenberg I, Holy A (2004) The substrate activity
of (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine diphosphate toward DNA polymerases alpha, delta and epsilon. Antivir Chem Chemother 15:23–33
42. Magee WC, Valiaeva N, Beadle JR, Richman DD, Hostetler KY, Evans DH (2011) Antimicrob Agents Chemother 55(11):5063–5072
43. De Clercq E (2011) The clinical potential of the acyclic (and cyclic) nucleoside phosphonates.
The magic of the phosphonate bond. Biochem Pharmacol 82:99–109
44. Andrei G, Snoeck R (2010) Cidofovir activity against poxvirus infections. Viruses 2(12):
2803–2830
45. Corey L, Benedetti J, Critchlow C, Mertz G, Douglas J, Fife K, Fahnlander A, Remington
ML, Winter C, Dragavon J (1983) Treatment of primary first-episode genital herpes simplex
virus infections with acyclovir: results of topical, intravenous and oral therapy. J Antimicrob
Chemother 12(Suppl B):79–88
46. Serota FT, Starr SE, Bryan CK, Koch PA, Plotkin SA, August CS (1982) Acyclovir treatment
of herpes zoster infections: use in children undergoing bone marrow transplantation. JAMA
247:2132–2135
47. De Clercq E (2004) Discovery and development of BVDU (brivudin) as a therapeutic for the
treatment of herpes zoster. Biochem Pharmacol 68:2301–2315
48. Superti F, Ammendolia MG, Marchetti M (2008) New advances in anti-HSV chemotherapy.
Curr Med Chem 15:900–911
49. Nichols WG, Boeckh M (2000) Recent advances in the therapy and prevention of CMV infections. J Clin Virol 16:25–40
50. Sarisky RT, Bacon TH, Boon RJ, Duffy KE, Esser KM, Leary J, Locke LA, Nguyen TT, Quail
MR, Saltzman R (2003) Profiling penciclovir susceptibility and prevalence of resistance of
herpes simplex virus isolates across eleven clinical trials. Arch Virol 148(9):1757–1769